News

Highlights from the June 2016 American Society of Clinical ...

Highlights from the June 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

June 20, 2016

(June 20, 2016) Highlights from the June 2016 American Society of Clinical Oncology (ASCO) Annual Meeting by Susan Leighton, Ovarian Cancer Survivor and Research Advocate Since the first time I attended ASCO I have seen the number of abstracts presented about ovarian cancer increase significantly as understanding of the disease has expanded. No longer do we hear … Continued

OCRFA Research Sheds Light on Role of STAT3 in Ovarian Cancer

OCRFA Research Sheds Light on Role of STAT3 in Ovarian Cancer

June 17, 2016

(June 17, 2016) An OCRFA funded study recently published in Oncogene investigated the role that protein STAT3 plays in the activation and metastasis of ovarian cancer cells. Many women with ovarian cancer develop fluid in the abdomen, which contains cancer cells. Those cells, coupled with a high activation of STAT3, can spread to other areas … Continued

OCRFA Research Shows Genetic Subtypes Linked to Increased R...

OCRFA Research Shows Genetic Subtypes Linked to Increased Risk of Ovarian Cancer

June 9, 2016

(June 9, 2016) A ten year, OCRFA-funded study has revealed the effect that the human leukocyte antigen (HLA) genes, which help regulate the body’s immune system, have on how the body responds to treatment of epithelial ovarian cancer. The scientists report that women with certain types of HLA may have an increased risk of ovarian … Continued

Risk Factors and Outcomes for Chemotherapy Refusal

Risk Factors and Outcomes for Chemotherapy Refusal

June 7, 2016

(June 7, 2016) The Journal of the National Comprehensive Cancer Network recently published a study that looked at the difference in outcomes between two groups of epithelial ovarian cancer patients: those who received recommended, multiagent chemotherapy and those who chose not to undergo the recommended treatment. After tracking thousands of patients in both groups, the … Continued

The Impact of BMI on IP Therapy

The Impact of BMI on IP Therapy

May 25, 2016

(May 25, 2016) A new study published in the International Journal of Gynecological Cancer earlier this month investigated the impact of body mass index (BMI) on completion, complications, and clinical outcomes of intraperitoneal (IP) chemotherapy in patients with advanced-stage ovarian cancer. The study followed ninety two patients through a minimum of one cycle of IP … Continued

Webinar: Clinical Trials: What you need to know

Webinar: Clinical Trials: What you need to know

May 9, 2016

Oliver Dorigo, MD, PhD, Director of the Stanford Gynecologic Oncology Clinical Care Program and Director of Stanford Obstetrics and Gynecology’s Division of Gynecologic Oncology provided an introduction to clinical trials for ovarian cancer patients. Dr. Dorigo discussed what clinical trials are, why they are important and how they work, the pros and cons of enrolling … Continued

Long Term Survival Study Recruiting Participants

Long Term Survival Study Recruiting Participants

May 9, 2016

The Consortium for Long-Term Survival — is bringing together research groups worldwide. These groups include survivors, patient advocates and advocacy groups, (not just researchers) with the goal of “FINDING THE KEY TO LONG-TERM SURVIVAL FOR ALL WOMEN.” RECRUITING NOW: 8+ year survivors, STAGE 3 or 4 ONLY, contact Giulia Fulci, gfulci@partners.org or 617-643-7261. View more … Continued

OCRFA Research Helps Explain Resistance to Chemotherapy

OCRFA Research Helps Explain Resistance to Chemotherapy

May 4, 2016

(May 4, 2016) Research funded in part by an OCRFA research grant to Dr. Weiping Zou at the University of Michigan has shown that the sensitivity and resistance to cancer chemotherapies is not fully explained by genomic mechanisms as it has previously thought.  In fact, it may be affected by effector T cells (cells that defend … Continued

Irregular Periods May Increase Ovarian Cancer Risk

Irregular Periods May Increase Ovarian Cancer Risk

May 2, 2016

(May 2, 2016) Research published last month in the International Journal of Cancer showed an unexpected finding: young women with irregular menstrual periods may be at higher risk of developing—and dying from—ovarian cancer later in life. The study provides the first evidence linking abnormally long cycles or missed periods to higher ovarian cancer risk. It … Continued

Stand Up To Cancer Supports “Innovation in Collaboration” i...

Stand Up To Cancer Supports “Innovation in Collaboration” in Cancer Research with $1 Million for Five Teams through Phillip A. Sharp Awards

May 2, 2016

May 2, 2016 – Stand Up To Cancer (SU2C) has awarded a total of $1 million to five teams of cancer researchers to advance “innovation in collaboration” among SU2C-­‐affiliated scientists. Each team, consisting of researchers from different SU2C-­‐supported “Dream Teams” or research programs, will receive a grant of $200,000 to support new research projects stemming … Continued

Stand Up To Cancer Supports “Innovation in Collaboration” i...

Stand Up To Cancer Supports “Innovation in Collaboration” in Cancer Research

May 2, 2016

Stand Up To Cancer Supports “Innovation in Collaboration” in Cancer Research with $1 Million for Five Teams through Phillip A. Sharp Awards May 2, 2016 – Stand Up To Cancer (SU2C) has awarded a total of $1 million to five teams of cancer researchers to advance “innovation in collaboration” among SU2C-affiliated scientists. Each team, consisting … Continued

Hormone Therapy Safe After Nonserous Ovarian Cancer

Hormone Therapy Safe After Nonserous Ovarian Cancer

April 25, 2016

(April 25, 2016) New findings published online this month in Obstetrics and Gynecology suggest that hormone therapy (HT) can be used safely to manage menopausal symptoms in women who have undergone treatment for nonserous epithelial ovarian cancer. The study showed no reduction in overall survival with HT use in the entire study population, and it … Continued